Form 4: Dyne Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
John Cox, CEO & President and a Director of Dyne Therapeutics, Inc., sold 5,658 shares of common stock on September 8, 2026 for $18.88 per share.
Summary
- Open-market sale: disposed of 5,658 Common Stock at $18.88 ($106,823) on September 8, 2026; holds 357,507 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $106,823 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
John Cox — Director, Officer (CEO & President)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-08 | Open-market sale | Common Stock | 5,658 | $19 | $106.8K | 357,507 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-08 | Open-market sale (5,658 shares) |
Keywords
insider transaction, Form 4, DYN, Dyne Therapeutics, Inc., bearish, John Cox
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.